Abstract:In the past 50 years, the treatment of this cancer has evolved from a regimen of preoperative radiation therapy followed by hysterectomy, to individualized management consisting of surgical treatment with or without additional therapy depending on whether various risk factors are identified. After the diagnosis of endometrial carcinoma has been histologically confirmed, uterine and extrauterine risk factors affect the probability of retroperitoneal lymph node involvement and subsequent survival. Surgical staging is a critical component for the proper diagnosis and management of all endometrial carcinomas. FIGO stage is the most powerful predictor of prognosis. Surgical staging is feasible by minimally invasive techniques. Patients with significant medical comorbidities who are not acceptable candidates for surgery may be managed by alternative means. Women with EC are diagnosed under the age of 40 may be eligibile for nonoperative management if there is no clear evidence of myometrial invasion. As the contemporary management of EC continues to evolve, and the indications for lymph node dissection remain controversial. Minimally invasive management of EC has increasingly been integrated into standard practice. In 2006, The Cancer Genome Atlas (TCGA) began with studies in glioblastoma and high-grade serous ovarian cancer. The National Institutes of Health committed major resources to TCGA to collect and characterize the genomic landscape of more than 20 cancer types. In 2013, TCGA published findings for endometrial cancers. Only serous and endometrioid subtypes were accrued in the endometrial cancer project. TCGA has reclassified endometrioid and serous endometrial cancers in four broad categories using comprehensive genomic approaches. One-third of the cancers is characterized by microsatellite instability (MSI) and associated hyper-mutation. The cancers without MSI can be further separated into two groups. Serous cases with extensive DNA copy number alterations and genomic instability comprise one group, and endometrioid cases with few or only focal copy number alterations comprise the other. A smaller fourth sub-group contains samples with very high mutation rates and is characterized by mutations in POLE. Molecular features can be distinctly overlaid onto these four sub-classifications, and each have important clinical implications that are currently being used in both clinical practice and clinical trial design. In this educational presentation, we will discuss the management of newly diagnosed endometrial cancers, review the molecular classification of endometrial cancers, and identify approaches that incorporate these findings into clinical care and clinical trial design. Citation Format: Douglas A. Levine. Management of newly diagnosed endometrial cancers and molecular classification [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl) nr IA002.

Practical Updates and Diagnostic Challenges in Endometrial Carcinoma.

A Clinicopathologic and Prognostic Analysis of 115 Cases of Endometrial Carcinoma

A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas

Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer

Endometrial Cancer: An Update on Prognostic Pathologic Features and Clinically Relevant Biomarkers

Evaluation of the Accuracy of Intra-Operative Gross Examination for the Surgical Management of Endometrial Cancer.

Update in the molecular classification of endometrial carcinoma

Histopathologic diagnosis of endometrial precancers: Updates and future directions

[Endometrial carcinomas in 2021: What to say and what to do?]

Accuracy of Tumor Grade by Preoperative Curettage and Associated Clinicopathologic Factors in Clinical Stage I Endometriod Adenocarcinoma

Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade)

Management of Endometrial Cancer: A Comparative Review of Guidelines

Preoperative and Intraoperative Assessment of Myometrial Invasion in Patients with FIGO Stage I Non-Endometrioid Endometrial Carcinoma—a Large-Scale, Multi-Center, and Retrospective Study

Uncommon Morphologic Types of Endometrial Cancer and Their Mimickers: How Much Does Molecular Classification Improve the Practice for Challenging Cases?

Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors

Surgical treatment of high stage endometrial cancer: current perspectives

Abstract IA002: Management of newly diagnosed endometrial cancers and molecular classification

Clinicopathological Analysis of Carcinoma Endometrium at a Tertiary Care Centre in Chennai – A Retrospective Study

Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment

Contemporary Diagnostic Reporting for Prostatic Adenocarcinoma: Morphologic Aspects, Molecular Correlates, and Management Perspectives

Molecular classification of endometrial carcinoma: a clinically oriented review